An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy.

Copyright © 2023 FULLCRO S.R.L. - TUTTI I DIRITTI RISERVATI
per contatti riguardanti lo Studio SURE sure@fullcro.org